Patents by Inventor Anette Graven Sams

Anette Graven Sams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alcohol derivatives as KV7 potassium channel openers
    Patent number: 11548849
    Abstract: The present invention provides novel compounds (e.g., compounds of Formula I) which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: January 10, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Mario Rottlander, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Anette Graven Sams, Krestian Larsen
  • ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS
    Publication number: 20220380300
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: July 20, 2022
    Publication date: December 1, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES
    Publication number: 20220280455
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: July 30, 2020
    Publication date: September 8, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Anette Graven Sams, Mario Rottlãnder, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Jesper Frank Bastlund, Jelena Ivkovic, Karina Krøjer Søby, Morten Grupe Larsen
  • Alcohol derivatives as KV7 potassium channel openers
    Patent number: 11434199
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: September 6, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
    Publication number: 20220220095
    Abstract: The present invention provides N-(heteroaryl)methyl)-1-tosyl-1H-pyrazole-3-carboxamide derivatives of the structure Formula (I), which activate the Kv3 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and to the compounds and pharmaceutical compositions thereof for use in methods of medical treatment of disorders responsive to the activation of Kv3 potassium channels, such as e.g. neurological or psychiatric disorders for example epilepsy, schizophrenia, cognitive impairment associated with schizophrenia (CIAS), autism spectrum disorder, bipolar disorder, ADHD, anxiety-related disorders, depression, cognitive dysfunction, Alzheimer's disease, Fragile X syndrome, chronic pain, hearing loss, sleep and circadian disorders, and sleep disruption. Exemplary compounds are e.g.
    Type: Application
    Filed: April 24, 2020
    Publication date: July 14, 2022
    Inventors: Anette Graven SAMS, Lars Kyhn RASMUSSEN, Wanwan YU
  • ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
    Publication number: 20220204489
    Abstract: The present invention provides novel compounds which activate the Kv3 potassium channels. The compounds have the structure (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and use of the compounds to treat disorders responsive to the activation of Kv3 potassium channels.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 30, 2022
    Inventors: Anette Graven SAMS, Lars Kyhn RASMUSSEN, Wanwan YU
  • ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS
    Publication number: 20210032196
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Mario Rottlander, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Anette Graven Sams, Krestian Larsen
  • ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS
    Publication number: 20200172474
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
    Publication number: 20200131156
    Abstract: The present invention provides novel compounds which activate the Kv3 potassium channels. The compounds have the structure Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and use of the compounds to treat disorders responsive to the activation of Kv3 potassium channels.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 30, 2020
    Inventors: Anette Graven SAMS, Lars Kyhn RASMUSSEN, Wanwan YU, Paul Robert FLEMING
  • Alcohol derivatives of carboxamides as Kv7 potassium channel openers
    Patent number: 10590067
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Exemplary compounds of the invention have the structure of Formula 1. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 17, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS
    Publication number: 20190256456
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: February 20, 2018
    Publication date: August 22, 2019
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR
    Publication number: 20180250277
    Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.
    Type: Application
    Filed: December 29, 2017
    Publication date: September 6, 2018
    Inventors: Jorgen Eskildsen, Anette Graven Sams, Ask Puschl
  • Positive allosteric modulators of nicotinic acetylcholine receptor
    Patent number: 9889122
    Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: February 13, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Jorgen Eskildsen, Anette Graven Sams, Ask Puschl
  • New Positive Allosteric Modulators or Nicotinic Acetylcholine Receptor
    Publication number: 20170079967
    Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Jorgen Eskildsen, Anette Graven Sams, Ask Puschl
  • Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
    Patent number: 9586961
    Abstract: The invention relates to compounds of general formula (I) wherein R1, R2, R3, R4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immuno-suppression would be desirable for example in organ transplantation.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: March 7, 2017
    Assignee: LEO PHARMA A/S
    Inventors: Simon Felbdæk Nielsen, Daniel R. Greve, Gunnar Grue-Sørensen, Carsten Ryttersgaard, Søren Christian Schou, Anette Graven Sams
  • Positive allosteric modulators of nicotinic acetylcholine receptor
    Patent number: 9549919
    Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: January 24, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Jorgen Eskildsen, Anette Graven Sams, Ask Puschl
  • New positive allosteric modulators of nicotinic acetylcholine receptor
    Publication number: 20150315130
    Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.
    Type: Application
    Filed: December 9, 2013
    Publication date: November 5, 2015
    Applicant: H. Lundbeck A/S
    Inventors: Jørgen Eskildsen, Anette Graven Sams, Ask Püschl
  • POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR
    Publication number: 20150231121
    Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.
    Type: Application
    Filed: May 5, 2015
    Publication date: August 20, 2015
    Inventors: Jorgen Eskildsen, Anette Graven Sams, Ask Puschl
  • Positive allosteric modulators of nicotinic acetylcholine receptor
    Patent number: 9050327
    Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: June 9, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Jørgen Eskildsen, Anette Graven Sams, Ask Püschl
  • Positive allosteric modulators of nicotinic acetylcholine receptor
    Patent number: 9023870
    Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: May 5, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Anette Graven Sams, Jørgen Eskildsen, Ask Puschl